Nelson Vergel
Founder, ExcelMale.com
Gut bacteria influence testosterone production in animal models, and testosterone changes the gut in return. No gut-derived molecule has yet been proven to regulate testosterone in humans.
The gut and the testes talk in both directions
Researchers call this network the microbiota-gut-testis axis. It links four systems: gut bacteria and the molecules they make, the intestinal barrier and immune system, the hypothalamic-pituitary-gonadal (HPG) axis, and the steroid-making machinery inside the testes.
The traffic runs both ways. Microbial molecules reach the testes and change testosterone output. Testosterone levels, in turn, reshape which bacteria thrive and what they produce.
Small daily hormone swings do little to gut bacterial diversity. Gut ecosystems are resilient. Large shifts are different. Puberty, castration and long-term androgen deprivation therapy cross what researchers call a threshold, and the microbial community restructures itself. A man's hormonal history may therefore shape his gut as much as his gut shapes his hormones.
What bacteria make matters more than which bacteria live there
Most microbiome studies count bacteria using 16S rRNA sequencing. A rise in one genus is a correlation. It does not prove a matching rise in the molecules that genus can produce.
Metabolite output depends on the bacterial strain, which genes it switches on, the food it receives, gut pH and how much the host absorbs. Two men with the same bacterial profile can produce very different amounts of the same signal. Useful research in this field now measures metabolite levels in blood and tissue, not bacterial headcounts.
The candidate signals
Three classes of gut microbial metabolites are the leading candidates for influencing testosterone. Each acts through different receptors, and some push testosterone up while others push it down.
One receptor detail matters for reading the literature. Primary bile acids such as chenodeoxycholic acid (CDCA) are the main FXR activators. DCA and LCA act mostly through TGR5, and LCA can also block the androgen receptor.
Serotonin results have conflicted for years. It stimulated testosterone in young animals and inhibited it in adults. A proposed triple-gate hypothesis explains the split: the effect depends on local serotonin concentration, which receptor subtype the Leydig cell expresses (5-HT1A or 5-HT2A), and the developmental stage of the testis.
Two routes from gut to testes
Gut signals reach the testes either directly through the blood or indirectly through host systems such as the brain and immune system. Many molecules use both.
The barrier route is the easiest to picture. Tight-junction proteins (ZO-1, occludin, MUC2) seal the gut wall. When the seal weakens, LPS enters the bloodstream and activates TLR4-driven inflammation. That inflammation suppresses Leydig cell testosterone output.
The brain route is less settled. The SCFA to GLP-1 to kisspeptin relay was shown in a female precocious puberty model. Whether it operates the same way in men is still under study.
The proof gap
None of the three metabolite classes has met the standard needed to call it a confirmed testosterone regulator. That standard has three parts, and all must be shown in the same living model:
The weak link is usually the first criterion. Lab studies often use doses the body does not reach.
The IPA work illustrates the gap. In mouse Leydig cells exposed to high glucose, 10 and 20 µM IPA reduced ER stress markers and apoptosis, and 20 µM restored steroidogenic gene expression (Jalili et al., 2025). Those doses sit roughly ten times above typical human plasma levels.
Herbal compounds and the evidence ladder
Several plant compounds restore testosterone in damaged animal models, and some appear to work through the gut. Fiber-like polysaccharides and oligosaccharides resist digestion and feed gut bacteria, which makes them useful test tools.
A four-level grading system separates correlation from causation:
CSP1 (level M4). In mice made obese on a high-fat diet, CSP1 restored serum testosterone, sperm count and motility. It cut LPS-producing bacteria, enriched SCFA producers such as Lachnospiraceae, raised ZO-1, occludin and MUC2, and suppressed testicular TLR4/MyD88/NF-κB signaling. Fecal transplant confirmed that the gut microbiota carried the effect (Huan et al., 2025).
MOS (level M3). In mice with gossypol-induced low sperm motility, MOS improved motility and restored testosterone. It enriched Anaerococcus. Transplanting Anaerococcus activated testicular IGF-1/PI3K/mTOR signaling and improved motility, and the mTOR blocker rapamycin cancelled the gains (Hu et al., 2026). The study did not show that Anaerococcus alone restores testosterone.
All of this work is in rodents. None of these studies includes human data.
What this means for men today
No probiotic, prebiotic or herbal product has been shown to raise testosterone in men through the gut. Products marketed that way are ahead of the evidence.
The best-supported mechanism is the barrier-inflammation route. A leaky gut lets endotoxin into the blood, and the resulting inflammation suppresses Leydig cells. Obesity and high-fat diets damaged this barrier in the animal work. Dietary fiber feeds the bacteria that make SCFAs, which help keep the barrier sealed. Those are reasonable habits for metabolic health regardless of what the testosterone research eventually shows.
For men on testosterone therapy, the picture is different. Exogenous testosterone suppresses the testes' own production, so gut signals acting on Leydig cells have less influence on serum levels. The open question runs the other way: whether a large, sustained change in androgen levels reshapes the gut microbiome, as castration and androgen deprivation do. That has not been studied directly in men starting TRT.
The field needs isotope tracing of metabolites from gut to testicular fluid, single-cell mapping of testicular receptors, and receptor knockouts that abolish the effect. Until that work is done, treat the gut-testis axis as a promising hypothesis.
Sources
The gut and the testes talk in both directions
Researchers call this network the microbiota-gut-testis axis. It links four systems: gut bacteria and the molecules they make, the intestinal barrier and immune system, the hypothalamic-pituitary-gonadal (HPG) axis, and the steroid-making machinery inside the testes.
The traffic runs both ways. Microbial molecules reach the testes and change testosterone output. Testosterone levels, in turn, reshape which bacteria thrive and what they produce.
Small daily hormone swings do little to gut bacterial diversity. Gut ecosystems are resilient. Large shifts are different. Puberty, castration and long-term androgen deprivation therapy cross what researchers call a threshold, and the microbial community restructures itself. A man's hormonal history may therefore shape his gut as much as his gut shapes his hormones.
What bacteria make matters more than which bacteria live there
Most microbiome studies count bacteria using 16S rRNA sequencing. A rise in one genus is a correlation. It does not prove a matching rise in the molecules that genus can produce.
Metabolite output depends on the bacterial strain, which genes it switches on, the food it receives, gut pH and how much the host absorbs. Two men with the same bacterial profile can produce very different amounts of the same signal. Useful research in this field now measures metabolite levels in blood and tissue, not bacterial headcounts.
The candidate signals
Three classes of gut microbial metabolites are the leading candidates for influencing testosterone. Each acts through different receptors, and some push testosterone up while others push it down.
| Metabolite class | Main molecules | How they are made | Proposed effect on testosterone |
|---|---|---|---|
| Short-chain fatty acids (SCFAs) | Acetate, propionate, butyrate | Bacterial fermentation of dietary fiber in the colon | Mostly indirect: trigger GLP-1 release via GPR41/GPR43 on gut L-cells, tighten the gut barrier and cut endotoxin leakage. In animal models, butyrate inside the testis raises StAR, CYP11A1 and LH receptor expression. |
| Secondary bile acids | Deoxycholic acid (DCA), lithocholic acid (LCA), ursodeoxycholic acid (UDCA) | Gut bacteria (including Clostridium scindens and Eggerthella lenta) convert liver-made primary bile acids | Mixed. Testicular FXR activation induces SHP and DAX-1, which suppress steroidogenesis and blunt the Leydig cell response to LH. High DCA damages the gut lining and drives inflammation. Low-dose LCA protects the barrier via TGR5. |
| Tryptophan derivatives | Indoles (IPA, IAA), kynurenines (KYN, KYNA), serotonin (5-HT) | Bacteria metabolize dietary tryptophan or steer host enzymes | Indoles activate AhR in Leydig cells, reduce ER stress and restore steroidogenic genes. Kynurenic acid tracks with suppressed sperm production. Serotonin can raise or lower testosterone depending on context. |
One receptor detail matters for reading the literature. Primary bile acids such as chenodeoxycholic acid (CDCA) are the main FXR activators. DCA and LCA act mostly through TGR5, and LCA can also block the androgen receptor.
Serotonin results have conflicted for years. It stimulated testosterone in young animals and inhibited it in adults. A proposed triple-gate hypothesis explains the split: the effect depends on local serotonin concentration, which receptor subtype the Leydig cell expresses (5-HT1A or 5-HT2A), and the developmental stage of the testis.
Two routes from gut to testes
Gut signals reach the testes either directly through the blood or indirectly through host systems such as the brain and immune system. Many molecules use both.
| Feature | Direct route | Indirect route |
|---|---|---|
| Where it acts | Inside the testis (Leydig, Sertoli and germ cells) | Outside the testis (gut lining, HPG axis, immune system) |
| Example molecules | Secondary bile acids, IPA, butyrate in testicular tissue | SCFAs, bacterial endotoxin (LPS), gut-derived serotonin |
| Host relay needed | No | Yes: GLP-1, kisspeptin or inflammatory cytokines |
| Key receptors | Testicular FXR, TGR5, AhR, LHR/cAMP/PKA | Gut GPR41/GPR43, TLR4/MyD88/NF-κB, hypothalamic Kiss1/GPR54 |
The barrier route is the easiest to picture. Tight-junction proteins (ZO-1, occludin, MUC2) seal the gut wall. When the seal weakens, LPS enters the bloodstream and activates TLR4-driven inflammation. That inflammation suppresses Leydig cell testosterone output.
The brain route is less settled. The SCFA to GLP-1 to kisspeptin relay was shown in a female precocious puberty model. Whether it operates the same way in men is still under study.
The proof gap
None of the three metabolite classes has met the standard needed to call it a confirmed testosterone regulator. That standard has three parts, and all must be shown in the same living model:
- Tissue exposure. The metabolite reaches testicular interstitial fluid at effective concentrations.
- Receptor engagement. It activates its receptor on Leydig cells at those measured concentrations.
- Biological effect. That activation changes steroidogenic gene expression and testosterone output.
The weak link is usually the first criterion. Lab studies often use doses the body does not reach.
| Metabolite | Level used in lab studies | Level measured in humans | Problem |
|---|---|---|---|
| Indole-3-propionic acid (IPA) | 10–20 µM | About 1–2 µM total in plasma | IPA is heavily protein-bound, so free IPA is lower still |
| Secondary bile acids | Micromolar levels needed to activate testicular FXR/TGR5 | About 0.1–1 µM in circulation | Barely reaches, or falls short of, activation thresholds |
| SCFAs | Cell-culture concentrations | Low systemic levels | Colon cells and the liver clear an estimated 70–90% before they reach general circulation |
The IPA work illustrates the gap. In mouse Leydig cells exposed to high glucose, 10 and 20 µM IPA reduced ER stress markers and apoptosis, and 20 µM restored steroidogenic gene expression (Jalili et al., 2025). Those doses sit roughly ten times above typical human plasma levels.
Herbal compounds and the evidence ladder
Several plant compounds restore testosterone in damaged animal models, and some appear to work through the gut. Fiber-like polysaccharides and oligosaccharides resist digestion and feed gut bacteria, which makes them useful test tools.
A four-level grading system separates correlation from causation:
| Level | What the study shows | Examples |
|---|---|---|
| M4: closed-loop causality | Fecal microbiota transplant (FMT) proves the remodeled gut transfers the benefit | Cynomorium songaricum polysaccharide (CSP1) |
| M3: partial functional proof | Transferring one bacterial group reproduces part of the benefit | Morinda officinalis oligosaccharides (MOS) |
| M2: multi-omics association | Bacterial, metabolite and reproductive changes correlate statistically | Icariin, Portulaca oleracea polysaccharides, Panax ginseng |
| M1: parallel changes | Gut bacteria and testicular markers improve at the same time | Phloridzin, curcumin |
CSP1 (level M4). In mice made obese on a high-fat diet, CSP1 restored serum testosterone, sperm count and motility. It cut LPS-producing bacteria, enriched SCFA producers such as Lachnospiraceae, raised ZO-1, occludin and MUC2, and suppressed testicular TLR4/MyD88/NF-κB signaling. Fecal transplant confirmed that the gut microbiota carried the effect (Huan et al., 2025).
MOS (level M3). In mice with gossypol-induced low sperm motility, MOS improved motility and restored testosterone. It enriched Anaerococcus. Transplanting Anaerococcus activated testicular IGF-1/PI3K/mTOR signaling and improved motility, and the mTOR blocker rapamycin cancelled the gains (Hu et al., 2026). The study did not show that Anaerococcus alone restores testosterone.
All of this work is in rodents. None of these studies includes human data.
What this means for men today
No probiotic, prebiotic or herbal product has been shown to raise testosterone in men through the gut. Products marketed that way are ahead of the evidence.
The best-supported mechanism is the barrier-inflammation route. A leaky gut lets endotoxin into the blood, and the resulting inflammation suppresses Leydig cells. Obesity and high-fat diets damaged this barrier in the animal work. Dietary fiber feeds the bacteria that make SCFAs, which help keep the barrier sealed. Those are reasonable habits for metabolic health regardless of what the testosterone research eventually shows.
For men on testosterone therapy, the picture is different. Exogenous testosterone suppresses the testes' own production, so gut signals acting on Leydig cells have less influence on serum levels. The open question runs the other way: whether a large, sustained change in androgen levels reshapes the gut microbiome, as castration and androgen deprivation do. That has not been studied directly in men starting TRT.
The field needs isotope tracing of metabolites from gut to testicular fluid, single-cell mapping of testicular receptors, and receptor knockouts that abolish the effect. Until that work is done, treat the gut-testis axis as a promising hypothesis.
Sources
- Huan P, et al. Cynomorium songaricum polysaccharide attenuates high-fat diet-induced testicular dysfunction by modulating the gut microbiota. Int J Biol Macromol. 2025;335:149114. doi:10.1016/j.ijbiomac.2025.149114
- Hu J, et al. Morinda officinalis oligosaccharides improves sperm motility via the gut microbiota and the IGF-1/PI3K/mTOR signaling pathway. Front Endocrinol. 2026;16:1711475. doi:10.3389/fendo.2025.1711475
- Jalili C, et al. Mitigation of hyperglycemia-induced Leydig cell dysfunction by gut derived indole-3-propionic acid. Reprod Toxicol. 2025;137:108987. doi:10.1016/j.reprotox.2025.108987
